Sarah Cannon Research Institute Presents Latest Findings on Lung Cancer Clinical Trials During Thoracic Symposium
SCRI researcher authors five studies selected for presentation
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sep 6, 2012 - David R. Spigel, M.D., director of lung cancer research at Sarah Cannon Research Institute (SCRI), presents findings of two clinical trials and co-authors three additional studies selected for presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology Chicago Marriott Downtown Magnificent Mile in Chicago, September 6-8.
“The significant research being presented in these studies offers a novel combination of therapies seeking to improve clinical outcomes for patients with specific lung cancer subtypes,” SCRI Chief Medical Officer Howard A. Burris III, M.D. said.
Dr. Spigel will present results of a randomized phase II study of pazopanib or placebo in combination with erlotinib in patients with advanced non-small-cell lung cancer at Oral Abstract Session 1 on Thursday, September 6, from 4:00 to 4:10 p.m. CST. He also authors a poster presentation on a phase I/II study of the CD56-targeting antibody-drug conjugate, lorvotuzumab mertansine, in combination with carboplatin/etoposide in patients with solid tumors including small cell lung cancer at the Poster Viewing Session and Reception on Thursday, September 6, from 5:00 to 6:30 p.m. CST.
Dr. Spigel co-authored LBPL1, a randomized, phase III superiority study of pemetrexed (Pem) plus carboplatin (Cb) plus bevacizumab (B) followed by maintenance Pem+B versus paclitaxel+Cb+B followed by maintenance B in patients with stage IIIB or IV non-squamous non-small cell lung cancer. SCRI accrued 139 of 900 patients (15%) for this pivotal study, which is being presented as a late breaking abstract in the Plenary Session on Friday, September 7, from 1:30 to 1:40 p.m. CST.
Additionally, Dr. Spigel co-authored an abstract that will share results of the clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer being presented in the Plenary Session on Friday, September 7, from 1:00 to 1:10 p.m. CST. He is also an author of LBPL2, a randomized, double-blind, placebo-controlled phase II trial of bavituximab plus docetaxel in patients with previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (top-line results), which will be presented in the Plenary Session on September 7, from 1:40 to 1:50 p.m. CST.
About the Chicago Multidisciplinary Symposium in Thoracic Oncology
The 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology will offer valuable information on the multidisciplinary treatment approach for thoracic malignancies. This multidisciplinary meeting will promote interaction between the surgery, medical oncology and radiation oncology disciplines to achieve the best possible outcome for thoracic cancer patients. The meeting will also bring together physician specialists from around the world for interdisciplinary discussions on the latest research and state-of-the-art care for thoracic cancers.
Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites. For more information, please visit sarahcannonresearch.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50399851&lang=en
Contact: Sarah Cannon Research Institute
Anna Walker, 615-329-7216
Posted: September 2012